Search

Regeneron Pharmaceuticals Inc

Aperta

SettoreSettore sanitario

653.39 -3.03

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

647.87

Massimo

675.99

Metriche Chiave

By Trading Economics

Entrata

-117M

727M

Vendite

-279M

3.6B

P/E

Media del settore

16.527

62.58

EPS

9.47

Rendimento da dividendi

0.53

Margine di Profitto

20.17

Dipendenti

15,343

EBITDA

-234M

967M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+20.69% upside

Dividendi

By Acuity

Rendimento da dividendi

Media del settore

0.53%

2.19%

Utili prossimi

30 lug 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-7.6B

70B

Apertura precedente

656.42

Chiusura precedente

653.39

Notizie sul Sentiment di mercato

By Acuity

40%

60%

102 / 340 Classifica in Healthcare

Regeneron Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 lug 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

17 lug 2026, 19:26 UTC

Social Media
News

Regeneron Pharmaceuticals faces a class action lawsuit from Levi & Korsinsky, LLP, contributing to ongoing declines in the stock amid market volatility.

16 lug 2026, 20:03 UTC

Regeneron Pharmaceuticals is trading higher, supported by gains in the Biotechnology sub-sector amid a strong broader market performance today.

15 lug 2026, 19:16 UTC

Regeneron Pharmaceuticals Inc shares are higher Wednesday, recovering from an earlier dip and remaining above the 20-day moving average. No specific news was identified.

13 lug 2026, 19:26 UTC

Regeneron Pharmaceuticals shares are lower today amid broader market declines driven by rising oil prices and geopolitical tensions. No specific company news was identified.

11 lug 2026, 00:01 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reflecting a notable gain near the upper end of its one-month trading range.

10 lug 2026, 19:26 UTC

Correlated Moves

Regeneron Pharmaceuticals Inc shares declined amid broader biotechnology sector pressures and geopolitical tensions, despite earlier reaching a session high before pulling back.

9 lug 2026, 23:51 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours following a weak trading session, despite a report showing a decrease in initial jobless claims.

8 lug 2026, 19:53 UTC

News

Regeneron Pharmaceuticals shares are lower, pressured by declines in the Biotechnology sector and a reduced price target of $730 from Morgan Stanley.

7 lug 2026, 23:06 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, supported by stable performance and positioning above the 20-day moving average.

6 lug 2026, 23:01 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline amid mixed market sentiment.

2 lug 2026, 23:26 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, despite a lower-than-expected jobs report easing rate hike fears and boosting sentiment for some risk assets.

1 lug 2026, 19:16 UTC

Regeneron Pharmaceuticals is trading higher, reflecting positive biotechnology sector performance. The stock remains above its 20-day moving average and near a one-month peak.

30 giu 2026, 23:16 UTC

Regeneron Pharmaceuticals shares remain roughly flat in after-market trading, following three consecutive sessions of declines and no specific news identified.

29 giu 2026, 23:06 UTC

News

Regeneron Pharmaceuticals will join the FDA's PreCheck Pilot Program to enhance domestic drug manufacturing. Shares are trading lower in after-market hours.

26 giu 2026, 23:36 UTC

Regeneron Pharmaceuticals Inc shares are trading higher in after-market hours, moving within a notable range above their 20-day moving average.

25 giu 2026, 23:16 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, retracing from an early peak following five consecutive daily gains. No specific news was identified.

24 giu 2026, 23:01 UTC

Regeneron Pharmaceuticals Inc shares are lower after-market hours, continuing a decline since Wednesday's close amid positive sentiment in the financial sector.

23 giu 2026, 23:06 UTC

Regeneron Pharmaceuticals Inc shares are trading lower in after-market hours. Broader market trends may be influencing the stock's movement amid European market declines.

22 giu 2026, 19:56 UTC

Social Media
News

Regeneron Pharmaceuticals' cemdisiran submissions accepted by the FDA and European Medicines Agency. Shares are gaining amid positive regulatory developments.

18 giu 2026, 23:51 UTC

Regeneron Pharmaceuticals traded roughly flat in after-market hours, reflecting a slight decline since Thursday's close and remaining near the lower end of its one-month range.

17 giu 2026, 19:53 UTC

Macro Event

Regeneron Pharmaceuticals is declining in Wednesday's session, despite positive U.S. retail sales data. Shares remain below their 20-day moving average.

16 giu 2026, 19:16 UTC

Regeneron Pharmaceuticals Inc shares are lower today, with no specific news identified. Broader market sentiment may be affected by recent economic data.

15 giu 2026, 13:36 UTC

Regeneron Pharmaceuticals Inc shares are lower in pre-market hours. The stock is near the lower end of its one-month range, indicating routine price action.

13 giu 2026, 00:01 UTC

Regeneron Pharmaceuticals shares are modestly higher in after-market trading, though no specific news was identified to explain the movement.

12 giu 2026, 19:16 UTC

Shares of Regeneron Pharmaceuticals are modestly higher today, gaining traction after a flat start. The stock remains below its 20-day moving average.

11 giu 2026, 23:02 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, rebounding from earlier fluctuations despite no specific news to explain the movement.

10 giu 2026, 23:11 UTC

Regeneron Pharmaceuticals is trading higher in after-market hours, supported by a rise in the Biotechnology sub-sector. The stock remains near its one-month low.

9 giu 2026, 19:56 UTC

News

Regeneron Pharmaceuticals shares are higher following WHO's endorsement of its antibody therapy maftivimab for clinical trials against Bundibugyo ebolavirus.

8 giu 2026, 23:51 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, recovering from earlier lows amid broader market dynamics influenced by recent U.S. jobs data.

Confronto tra pari

Modifica del prezzo

Regeneron Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

20.69% in crescita

Previsioni per 12 mesi

Media 814.9 USD  20.69%

Alto 1,000 USD

Basso 641 USD

Basato su 21 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Regeneron Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

21 ratings

15

Acquista

6

Mantieni

0

Vendi

Sentiment

By Acuity

102 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
help-icon Live chat